Curiteva announced the achievement of over 10,000 levels successfully treated using the Inspire implant portfolio. With 5,000 interbodies implanted in just the last several months, this milestone underscores the rapid market adoption of the company’s 3D-printed Trabecular PEEK with HAFUSE technology. This achievement coincides with the alpha launch of the Inspire Standalone ALIF system and FDA clearance for the nano technology designation of Inspire 3D Printed Trabecular PEEK Technology.
Since launch in 2023, more than 10,000 interbodies have been implanted
The Inspire line comprises Cervical, Posterior, and Anterior Lumbar Portfolios
Inspire has addressed PEEK’s shortcomings by creating a hydrophilic, bioactive environment for cell attachment, proliferation, and healing
Curiteva doubled printer capacity in 2025 to meet growing demand
Curiteva plans to expand the application of the Inspire Technology into further surgical approaches, with standalone cervical and lateral systems currently prioritized for development.
David Schmidt, Curiteva’s Chief Commercial Officer, said, “With an impressive 60% growth in surgeries and a 90% increase in our surgeon customer base over the past year, Inspires momentum shows no signs of slowing down. 2026 is poised to be a breakout year for Inspire and Curiteva.”
Curiteva announced the achievement of over 10,000 levels successfully treated using the Inspire implant portfolio. With 5,000 interbodies implanted in just the last several months, this milestone underscores the rapid market adoption of the company's 3D-printed Trabecular PEEK with HAFUSE technology. This achievement coincides with the alpha...
Curiteva announced the achievement of over 10,000 levels successfully treated using the Inspire implant portfolio. With 5,000 interbodies implanted in just the last several months, this milestone underscores the rapid market adoption of the company’s 3D-printed Trabecular PEEK with HAFUSE technology. This achievement coincides with the alpha launch of the Inspire Standalone ALIF system and FDA clearance for the nano technology designation of Inspire 3D Printed Trabecular PEEK Technology.
Since launch in 2023, more than 10,000 interbodies have been implanted
The Inspire line comprises Cervical, Posterior, and Anterior Lumbar Portfolios
Inspire has addressed PEEK’s shortcomings by creating a hydrophilic, bioactive environment for cell attachment, proliferation, and healing
Curiteva doubled printer capacity in 2025 to meet growing demand
Curiteva plans to expand the application of the Inspire Technology into further surgical approaches, with standalone cervical and lateral systems currently prioritized for development.
David Schmidt, Curiteva’s Chief Commercial Officer, said, “With an impressive 60% growth in surgeries and a 90% increase in our surgeon customer base over the past year, Inspires momentum shows no signs of slowing down. 2026 is poised to be a breakout year for Inspire and Curiteva.”
Copy to clipboard 
